177 related articles for article (PubMed ID: 19884006)
41. Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.
Tang J; Hamajima T; Nakano M; Sato H; Dickerson SH; Lackey KE
Bioorg Med Chem Lett; 2008 Aug; 18(16):4610-4. PubMed ID: 18662874
[TBL] [Abstract][Full Text] [Related]
42. Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors.
Dinér P; Alao JP; Söderlund J; Sunnerhagen P; Grøtli M
J Med Chem; 2012 May; 55(10):4872-6. PubMed ID: 22559926
[TBL] [Abstract][Full Text] [Related]
43. New advances in synthesis and clinical aspects of pyrazolo[3,4-d]pyrimidine scaffolds.
Abdellatif KRA; Bakr RB
Bioorg Chem; 2018 Aug; 78():341-357. PubMed ID: 29627655
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and anti-tumor activities of novel pyrazolo[1,5-a]pyrimidines.
Li J; Zhao YF; Zhao XL; Yuan XY; Gong P
Arch Pharm (Weinheim); 2006 Nov; 339(11):593-7. PubMed ID: 17036367
[TBL] [Abstract][Full Text] [Related]
45. Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors.
Peat AJ; Boucheron JA; Dickerson SH; Garrido D; Mills W; Peckham J; Preugschat F; Smalley T; Schweiker SL; Wilson JR; Wang TY; Zhou HQ; Thomson SA
Bioorg Med Chem Lett; 2004 May; 14(9):2121-5. PubMed ID: 15080992
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells.
Manetti F; Pucci A; Magnani M; Locatelli GA; Brullo C; Naldini A; Schenone S; Maga G; Carraro F; Botta M
ChemMedChem; 2007 Mar; 2(3):343-53. PubMed ID: 17295370
[TBL] [Abstract][Full Text] [Related]
47. Functional Pyrazolo[1,5-
Arias-Gómez A; Godoy A; Portilla J
Molecules; 2021 May; 26(9):. PubMed ID: 34063043
[TBL] [Abstract][Full Text] [Related]
48. Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.
Wenglowsky S; Ahrendt KA; Buckmelter AJ; Feng B; Gloor SL; Gradl S; Grina J; Hansen JD; Laird ER; Lunghofer P; Mathieu S; Moreno D; Newhouse B; Ren L; Risom T; Rudolph J; Seo J; Sturgis HL; Voegtli WC; Wen Z
Bioorg Med Chem Lett; 2011 Sep; 21(18):5533-7. PubMed ID: 21802293
[TBL] [Abstract][Full Text] [Related]
49. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
[TBL] [Abstract][Full Text] [Related]
50. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.
Gould AE; Adams R; Adhikari S; Aertgeerts K; Afroze R; Blackburn C; Calderwood EF; Chau R; Chouitar J; Duffey MO; England DB; Farrer C; Forsyth N; Garcia K; Gaulin J; Greenspan PD; Guo R; Harrison SJ; Huang SC; Iartchouk N; Janowick D; Kim MS; Kulkarni B; Langston SP; Liu JX; Ma LT; Menon S; Mizutani H; Paske E; Renou CC; Rezaei M; Rowland RS; Sintchak MD; Smith MD; Stroud SG; Tregay M; Tian Y; Veiby OP; Vos TJ; Vyskocil S; Williams J; Xu T; Yang JJ; Yano J; Zeng H; Zhang DM; Zhang Q; Galvin KM
J Med Chem; 2011 Mar; 54(6):1836-46. PubMed ID: 21341678
[TBL] [Abstract][Full Text] [Related]
51. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
52. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
Eck MJ; Manley PW
Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
[TBL] [Abstract][Full Text] [Related]
53. Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
Zhang CH; Zheng MW; Li YP; Lin XD; Huang M; Zhong L; Li GB; Zhang RJ; Lin WT; Jiao Y; Wu XA; Yang J; Xiang R; Chen LJ; Zhao YL; Cheng W; Wei YQ; Yang SY
J Med Chem; 2015 May; 58(9):3957-74. PubMed ID: 25835317
[TBL] [Abstract][Full Text] [Related]
54. Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.
Waelchli R; Bollbuck B; Bruns C; Buhl T; Eder J; Feifel R; Hersperger R; Janser P; Revesz L; Zerwes HG; Schlapbach A
Bioorg Med Chem Lett; 2006 Jan; 16(1):108-12. PubMed ID: 16236504
[TBL] [Abstract][Full Text] [Related]
55. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
[TBL] [Abstract][Full Text] [Related]
56. Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.
Wenglowsky S; Ren L; Grina J; Hansen JD; Laird ER; Moreno D; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Sturgis HL; Voegtli WC; Vigers G; Willis B; Mathieu S; Rudolph J
Bioorg Med Chem Lett; 2014 Apr; 24(8):1923-7. PubMed ID: 24675381
[TBL] [Abstract][Full Text] [Related]
57. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.
Cho YS; Borland M; Brain C; Chen CH; Cheng H; Chopra R; Chung K; Groarke J; He G; Hou Y; Kim S; Kovats S; Lu Y; O'Reilly M; Shen J; Smith T; Trakshel G; Vögtle M; Xu M; Xu M; Sung MJ
J Med Chem; 2010 Nov; 53(22):7938-57. PubMed ID: 21038853
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors.
El-Deeb IM; Park BS; Jung SJ; Yoo KH; Oh CH; Cho SJ; Han DK; Lee JY; Lee SH
Bioorg Med Chem Lett; 2009 Oct; 19(19):5622-6. PubMed ID: 19700314
[TBL] [Abstract][Full Text] [Related]
59. Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel anti-proliferative agents: parallel synthesis for lead optimization of amide region.
Gopalsamy A; Yang H; Ellingboe JW; Tsou HR; Zhang N; Honores E; Powell D; Miranda M; McGinnis JP; Rabindran SK
Bioorg Med Chem Lett; 2005 Mar; 15(6):1591-4. PubMed ID: 15745803
[TBL] [Abstract][Full Text] [Related]
60. Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
El-Moghazy SM; George RF; Osman EEA; Elbatrawy AA; Kissova M; Colombo A; Crespan E; Maga G
Eur J Med Chem; 2016 Nov; 123():1-13. PubMed ID: 27474918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
